RenovoRx Stockholders Approve 2 Million Share Increase for Equity Incentive Plan

summarizeSummary

RenovoRx, Inc. held its annual meeting, where stockholders re-elected all directors, ratified the auditor, and approved a significant increase of 2,000,000 shares to the company's equity incentive plan.

check_boxKey Events · Corporate Governance and Compliance · RNXT

• Equity Incentive Plan Amended

  Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares of common stock. This increases the pool for future equity awards and represents approximately 4.4% of the company's outstanding shares.

• Directors Re-elected

  All six nominated directors, including Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP, were re-elected for a one-year term.

• Auditor Ratified

  Stockholders ratified the appointment of Frank, Rimerman + Co. LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

auto_awesomeAnalysis · RNXT · Life Sciences

RenovoRx stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares for future equity grants. This authorization represents approximately 4.4% of the company's outstanding shares and provides significant capacity for incentivizing employees and directors. While this introduces potential future dilution for existing shareholders, it is a common and often necessary step for life sciences companies to attract and retain key talent.